Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study - Aix-Marseille Université Access content directly
Journal Articles Targeted Oncology Year : 2021

Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study

Domains

Cancer
No file

Dates and versions

hal-03623633 , version 1 (29-03-2022)

Identifiers

Cite

Almudena Callejo, Sara Faouzi, Olivier Bouché, F. Bertucci, Thomas Chevalier, et al.. Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study. Targeted Oncology, 2021, 16 (4), pp.485-492. ⟨10.1007/s11523-021-00820-7⟩. ⟨hal-03623633⟩
11 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More